SEMIZLIK VA YURAK YETISHMOVCHILIGI RIVOJLANISHIDA UNING ROLI
Keywords:
Kalit so‘zlar: semizlik, yurak yetishmovchiligi, patofiziologiya, semizlik kardiomiyopatiyasi, semizlik paradoksi, insulin rezistentligi, SGLT2 ingibitorlari, GLP-1 agonistlari, bariatrik jarrohlik, miokard remodelingi.Abstract
Annotatsiya: Semizlik global miqyosda yurak yetishmovchiligi (YY) tarqalishining asosiy omillaridan biri bo‘lib, u miokardning tuzilmaviy va funksional buzilishlariga bevosita hissa qo‘shadi. Ushbu ilmiy maqolada semizlik va YY o‘rtasidagi bog‘liqlikni tushuntiruvchi gemodinamik, metabolik va immunologik mexanizmlar atroflicha o‘rganilgan. Tadqiqotda tana vazni indeksining ortishi bilan aylanib yuruvchi qon hajmining ko‘payishi, chap qorincha gipertrofiyasi va diastolik disfunksiya shakllanishi o‘rtasidagi aloqalar tahlil qilinadi. Shuningdek, visseral yog‘ to‘qimasi tomonidan ishlab chiqariladigan adipokinlarning surunkali yallig‘lanish va oksidativ stressni keltirib chiqarishdagi roli yoritilgan. Maqolaning klinik qismida semizlik paradoksi hodisasi tahlil qilinib, YY tashxisi qo‘yilgan bemorlarda ortiqcha vaznning omon qolish darajasiga ta’siri muhokama qilinadi. Boshqaruv strategiyalari doirasida SGLT2 ingibitorlari va GLP-1 retseptorlari agonistlarining yangi klinik dalillari, shuningdek, bariatrik jarrohlikning kardiometabolik samaradorligi ko‘rib chiqiladi. Natijalar shuni ko‘rsatadiki, semizlikka erta aralashuv va kompleks davolash choralari YY asoratlarini sezilarli darajada kamaytirishda hal qiluvchi ahamiyatga ega.
References
1. Grossman, E. (2025). Obesity and Cardiovascular Disease: Mechanistic Insights and Nutritional Management Strategies. Nutrients.
2. Pandey, A., et al. (2024). Tracking Pathways Linking Obesity with Heart Failure. Nutrients.
3. Kenchaiah, S., et al. (Framingham Heart Study). Obesity and risk of heart failure.
4. Poirier, P., et al. (2018). The Impact of Obesity on the Cardiovascular System.
5. Lavie, C. J., et al. Mechanisms of Heart Failure in Obesity.
6. Abdalla, M., et al. Prevalence of obesity in heart failure patients.
7. Westaby, S., et al. Obesity cardiomyopathy and sudden cardiac death.
8. Kenchaiah et al., 2002; Poirier et al., 2016
9. NCD-RisC, 2016; Poirier et al., 2016
10. Abel, E. D., et al. (2008). Cardiac remodeling in obesity.
11. Alpert, M. A., et al. (2016). Obesity and heart failure: epidemiology, pathophysiology, and clinical management.
12. Ebong, I. A., et al. (2014). Mechanisms of heart failure in obesity.
13. Hall, J. E., et al. (2015). Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms.
14. Kenchaiah, S., et al. (2002). Obesity and the risk of heart failure.
15. Kershaw, E. E., & Flier, J. S. (2004). Adipose tissue as an endocrine organ.
16. Koliaki, C., et al. (2019). Obesity and cardiovascular disease: extreme care for extreme obesity.
17. Lavie, C. J., et al. (2016). Obesity and heart failure: a comprehensive review.
18. Nadiyeva, Y. S., & Kenjayev, S. R. (2021). Semizlik va yurak qon-tomir tizimi kasalliklari.
19. Packer, M. (2018). Epicardial adipose tissue may mediate deleterious effects of obesity on heart failure with preserved ejection fraction.
20. Russo, I., & Frangogiannis, N. G. (2016). Diabetes-associated cardiac fibrosis: cellular effectors, molecular mechanisms and therapeutic opportunities.
21. Savji, N., et al. (2018). The obesity paradox in heart failure: is it real?
13.Alpert, M. A. (2001). Obesity cardiomyopathy: pathophysiology and evolution of the clinical syndrome. The American Journal of the Medical Sciences.
14.Avelar, E., et al. (2007). Left ventricular hypertrophy in severe obesity: interactions of blood pressure and metabolic variables. Hypertension.
15,Bozkurt, B., et al. (2016). Controversial markers of heart failure in obesity. JACC: Heart Failure.
16.Lopaschuk, G. D., et al. (2010). Myocardial fatty acid metabolism in health and disease. Physiological Reviews.
17.Obokata, M., et al. (2017). Role of obesity in HFpEF: the obese phenotype. JACC: Heart Failure.
18.Pandey, A., et al. (2015). Metabolic syndrome and risk of prevalent heart failure. Circulation: Heart Failure.
19.Anker, S. D., & von Haehling, S. (2011). The obesity paradox in heart failure: is it real? Journal of the American College of Cardiology.
20.Anker, S. D., et al. (2003). Cardiac cachexia: pathophysiology and clinical implications. Chest.
21.Gottdiener, J. S., et al. (2000). Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. Journal of the American College of Cardiology.
22.Horwich, T. B., et al. (2001). The relationship between body mass index and survival in patients with heart failure. Journal of the American College of Cardiology.
23.Sjöström, L., et al. (2012). Bariatric surgery and prevention of cardiovascular events in obese patients. New England Journal of Medicine.
24.Vest, A. R., et al. (2013). Bariatric surgery and cardiovascular outcomes: a systematic review. Heart.
25.Appel, L. J., et al. (1997). A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. New England Journal of Medicine.
26.Beaglehole, R., et al. (2011). Priority actions for the non-communicable disease crisis. The Lancet.
27.Kitzman, D. W., et al. (2016). Effect of caloric restriction or aerobic exercise training on peak oxygen consumption and quality of life in obese older patients with heart failure. JAMA.
28.Kosiborod, M. N., et al. (2023). Semaglutide in patients with heart failure with preserved ejection fraction and obesity. STEP-HFpEF Trial. New England Journal of Medicine.
29.McMurray, J. J. V., et al. (2019). Dapagliflozin in patients with heart failure and reduced ejection fraction. DAPA-HF Trial. New England Journal of Medicine.
30.Mozaffarian, D., et al. (2016). Heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation.
